Amgen recently started litigation against Teva over the biologic
drug filgrastim (Court File No. T-989-12). Filgrastim is a
granulocyte colony-stimulating factor analog that is used to treat
low neutrophil counts (neutropenia). It is primarily used to treat
patients with cancer. Amgen's filgrastim products have
generated billions of dollars in international sales annually.
Amgen is trying to use its patent to block Teva from getting its
marketing authorization from Health Canada (the Canadian
counterpart to the U.S. FDA)1. Amgen was able to start
the case because Teva's drug submission to Health Canada relies
on Amgen clinical data as a shortcut to approval (a drug that takes
this shortcut is called a "subsequent entry biologic" or
a "biosimilar"). This is the first time that a biosimilar
drug submission has been involved in this type of patent litigation
in Canada. When Teva filed its drug submission, it was also
required to assert that it would not infringe any valid Amgen
patent on Health Canada's Patent Register (this Patent Register
is similar to the U.S. Orange Book). This assertion was a trigger
that allowed Amgen to start the lawsuit.
The Canadian patent in the dispute (No. 1,341,537) expires in
2024. Amgen filed the case in the Federal Court on May 18, 2012,
and will have up to 2 years to get a court order blocking the
marketing authorization. Teva cannot launch its product in the
meantime, even if it meets Health Canada's safety and efficacy
Teva's filgrastim product (Tevagrastim) has been
marketed in Europe since 2008. It has not been marketed in the
United States. Amgen and Teva settled U.S. patent litigation on the
basis that Teva could launch in the U.S. in 2013.
The Teva drug submission also raises interesting regulatory
questions. It is a biologic drug, which is a protein produced by a
genetically engineered cell. Biologics are often much larger and
more complex than conventional chemically-synthesized small
molecule pharmaceuticals. This makes the comparison of biosimilars
to their approved counterparts more difficult. Health Canada
published a guidance document in March 2009 detailing the approval
requirements for subsequent entry biologics in
Teva should be required to provide comparative clinical trial
data of its product tested head-to-head against the Amgen drug.
This is a much higher standard than for conventional generic
pharmaceuticals which are approved upon showing bioequivalence and
without clinical trials. However, there remains much debate as to
how high the data requirements should be set for biosimilar
biologic drugs in view of their complexity.
1. The litigation is under the Patented Medicines
(Notice of Compliance) Regulations.
2. Health Canada, Guidance for Sponsors: Information
and Submission Requirements for Subsequent Entry Biology
(SEBs), Mar. 5, 2010.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Effective September 1, 2016, the Disposition of Surplus Real Property Regulation to the Ontario Education Act was amended with the intention to reduce barriers to the formation of health and community hubs in Ontario.
This appeal relates to two generic drug submissions for two different products: exemestane and infliximab. Both submissions cross-referenced the submission of another generic company that had received a Notice of Compliance.
Two recent decisions from the Supreme Court of Canada directly affect Quebec's farm businesses by confirming La Financière Agricole du Québec's discretion in the administration of the farm income stabilization program...
On October 6, 2016, the Ontario Legislature reintroduced the Patients First Act, 2016 as Bill 41. Bill 41 is very similar to its predecessor, Bill 210, which was introduced in June 2016, but makes some important changes to the previous bill.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).